Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBT Margin: 2022-2025

Historic EBT Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 165.14%.

  • InMed Pharmaceuticals' EBT Margin fell 2150.00% to 154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 171.13%, marking a year-over-year decrease of 3386.00%. This contributed to the annual value of 165.14% for FY2025, which is 165.00% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported EBT Margin of 165.14% as of FY2025, which was up 0.99% from 166.79% recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' EBT Margin ranged from a high of 165.14% in FY2025 and a low of 1,707.32% during FY2022.
  • Its 3-year average for EBT Margin is 174.60%, with a median of 166.79% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 151,546bps in 2023, then tumbled by 165bps in 2025.
  • MRY analysis of 4 years shows InMed Pharmaceuticals' EBT Margin stood at 1,707.32% in 2022, then soared by 89bps to 191.86% in 2023, then grew by 13bps to 166.79% in 2024, then rose by 1bps to 165.14% in 2025.
  • Its last three reported values are 165.14% in FY2025, 166.79% for FY2024, and 191.86% during FY2023.